EBOS Group Limited

EBO

NZEBOE0001S6

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
34.8 ^NZD	-0.57%		+0.14%	-1.97%

04-28	Jarden Securities Upgrades Ebos Group to Overweight from Neutral, Price Target is NZ$38.00	MT
04-26	New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO	MT

EBOS Group Limited Appoints Tracey Batten as an Independent Director, Effective 1 July 2021

June 14, 2021 at 10:32 pm

EBOS Group Limited advised of the appointment of Dr. Tracey Batten as an independent director, effective 1 July 2021. Dr. Batten is currently a non-executive director of Medibank Private Ltd.

Latest news about EBOS Group Limited

Jarden Securities Upgrades Ebos Group to Overweight from Neutral, Price Target is NZ$38.00	04-28	MT
New Zealand Shares Drop on Consumer Pessimism; Ebos Group Falls 3% After Appointing New CFO	04-26	MT
Ebos Group Appoints New CFO	04-25	MT
EBOS Group Limited Announces Chief Financial Officer Changes	04-25	CI
Evans & Partners Starts Ebos Group at Positive, Price Target is NZ$40.94	04-24	MT
Ebos Group Declares DRP Strike Price for Interim Dividend	03-13	MT
Morgan Stanley Adjusts EBOS Group’s Price Target to AU$37 From AU$38, Keeps at Overweight	03-06	MT
Morgan Stanley Adjusts EBOS’ Price Target to NZ$39.20 From NZ$41.05, Keeps at Overweight	03-06	MT
EBOS Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21	CI
EBOS Group Limited to Seek M&A	02-20	CI
Transcript : EBOS Group Limited, H1 2024 Earnings Call, Feb 21, 2024	02-20
EBOS Posts 7% Rise in Half Year FY24 Revenue, EPS Up 6.6%	02-20	MT
Correction: --EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Billion; Underlying EPS of AU$0.795	02-20	MT
EBOS Posts Half Year FY24 Revenue Up 7% to AU$6.58 Million; Underlying EPS of AU$0.795	02-20	MT
EBOS Group Limited Announces Interim Dividend of the Year Ending June 30, 2024, Payable 22 March 2024	02-20	CI
New Zealand shares post biggest weekly jump since Nov; Australia closed	01-26	RE
New Zealand shares snap 4-day rally but set for weekly gain; Australia closed	01-26	RE
New Zealand Shares Rise on Tuesday on Upbeat Economic Data; EBOS Raises Ownership in Transmedic to 90%	12-19	MT
EBOS Group Raises Transmedic Stake to 90% from 51%	12-19	MT
EBOS Group Limited acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.	12-18	CI
Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk	12-14	CI
EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit	12-05	CI
NZ's EBOS not to proceed with $2.44 billion Greencross acquisition	11-21	RE
NZ's EBOS not to proceed with acquisition in animal care segment	11-21	RE
EBOS Not to Proceed with Acquisition in Animal Care Segment	11-21	CI

EBOS Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is a marketer and distributor of animal care brands. Its segments include Healthcare, Animal Care and Corporate. The Healthcare segment includes sales of healthcare products in a range of sectors, own brands, retail healthcare, pharmacy, hospital and logistic services and wholesale activities. The Animal Care segment includes sales of animal care products in a range of sectors, own manufactured and contract manufactured brands, retail, and wholesale activities. It sources and supplies a range of surgical, medical, and pharmaceutical products. Its Community Pharmacy business includes Symbion, ProPharma, Pharmacy Wholesalers Russells, TerryWhite Chemmart, Good Price Pharmacy Warehouse, healthSAVE, Ventura Health, Minfos, DoseAid, Intellipharm, Endeavour Consumer Health, and Red Seal. Its contract logistics include Healthcare Logistics and Clinect.

Sector

Pharmaceuticals

Calendar

19/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for EBOS Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

34.8 NZD

Average target price

37.99 NZD

Spread / Average Target

+9.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
EBOS GROUP LIMITED	-1.97%	4.12B
CARDINAL HEALTH, INC.	-4.44%	23.38B
SINOPHARM GROUP CO. LTD.	+5.38%	8.58B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.83%	8.46B
HUADONG MEDICINE CO., LTD	-21.35%	7.94B
H. LUNDBECK A/S	+13.31%	5.3B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+10.84%	4.14B
GALENICA AG	-2.34%	3.87B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+20.72%	3.68B
MEDIPAL HOLDINGS CORPORATION	-2.14%	3.05B

Pharmaceuticals Wholesale